Himchandana Atluri, MD, details factors to consider ahead of TKI selection in patients with chronic myeloid leukemia.
Himachandana Atluri, MD
Advertisement
Himachandana Atluri, MD, is an assistant professor of medicine (Hematology and Oncology) at the Feinberg School of Medicine at Northwestern University in Chicago, Illinois.
Articles by Himachandana Atluri, MD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on OncLive
1
FDA Accepts BLA for Ivonescimab Plus Chemotherapy in EGFR-Mutant NSCLC After TKI Progression
2
FDA Approval Sought for Lirafugratinib in Second-Line, FGFR2-Altered Cholangiocarcinoma
3
Aligning Patient Goals and Toxicity Burden Are Key in First-Line Chemo Selection in Pancreatic Cancer
4
Dr Spencer on First-Line Chemo Selection in Metastatic Pancreatic Adenocarcinoma
5